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DOI:10.1097/HJH.0000000000001824Objective: Arterial ageing is characterized by increasing
arterial stiffness as measured by pulse wave velocity (PWV).
This process is enhanced in participants with early vascular
ageing (EVA), but slowed in participants with healthy
vascular ageing (HVA). We aimed to describe
characteristics of EVA and HVA in a transcontinental study
including 11 cohorts.
Methods: In all, 18 490 participants from the global MARE
Consortium, free of cardiovascular disease, participated
with data on PWV and cardiometabolic risk factors. We
defined HVA as the lowest 10% and EVA as the highest
10% of the standardized PWV distribution, adjusted for
age intervals. HVA individuals were compared with the
90% of non-HVA individuals with ANCOVA, adjusted for
age, sex and hypertension.
Results: The 1723 HVA participants were at the same age
as the rest of the population, more likely women (59.4 vs
57.0%), and with significantly lower levels of established
cardiovascular risk factors (blood pressure, lipids, glucose).
Similarly, the prevalence rate of obesity, diabetes mellitus,
hypertension and the metabolic syndrome was lower in
the HVA participants. In the presence of similar levels of
cardiovascular risk factors, HVA participants in the 50–64
years of age group presented lower PWV 5.8 (SD 0.5) vs.
7.4 (1.4) m/s (P<0.0001) than control individuals in the
35–49 years of age group, corresponding to an estimated
difference in chronological age of 14 years.
Conclusion: Participants with healthy vascular ageing
(HVA), belonging to the lowest end of the PWV
distribution, are in general characterized by an up to 14
years estimated younger biological (vascular) age than
those with higher PWV values, and have lower levels of
risk factors.
Keywords: age, arterial, blood pressure, cohort,
epidemiology, health, metabolic syndrome, risk factor
Abbreviations: AHA, active and healthy ageing; EVA,
early vascular ageing; FHS, Framingham Heart Study; HVA,
healthy vascular ageing; MAP, mean arterial pressure;
MARE Consortium, Metabolic syndrome and Artery
Research Consortium; PWV, pulse wave velocityJournal of HypertensionINTRODUCTIONL
arge arteries, as the aorta and itsmain branches, have a
conduit function by delivering the blood from the
center to the periphery, as well as a cushioning func-
tion, transforming the pulsatile flow at the heart level into a
steady flow at the tissue level. The cushioning function
depends on the viscoelastic properties of arterial walls and
on the arterial geometry [1,2]. With advancing age, there is
decreased elastin and increased collagen content in the
arterial wall, as well as increased cross-linking of collagen
fibres. This stiffening process is enhanced by the mechano-
transduction of shear stress and elevated blood pressure on
the smooth muscle cell differentiation of the arterial wall [3].
Increased arterial stiffness, indexed as pulse wave velocity
(PWV), is an established hall-mark of arterial ageing and can
effectively be used to calculate individual risk of cardiovas-
cular events and related disability [4–5]. Notably, at older
ages, the stiffening of large artery becomes progressively
independent of blood pressure levels [6].www.jhypertension.com 1
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Nilsson et al.Arterial ageing also reflects a genetic predisposition [7,8]
and exposure to multiple risk factors often occurring
together [9,10]. Arterial stiffening begins early in life [11],
as indicated and described by the early vascular ageing
(EVA) concept [12,13] with recent data showing high prev-
alence of the syndrome in individuals below 50 years of age
[14]. Therefore, a life-course approach aimed at the early
identification of individuals with accelerated arterial ageing
has been proposed as a mean to implement effective
prevention of cardiovascular events and improved hyper-
tension control [15].
Not all individuals, however, undergo this vascular age-
ing process in a uniform way. In fact, some individuals have
lower than expected PWV for a certain chronological age,
the opposite of EVA, and this has recently been called
Healthy Vascular Ageing (HVA) [16]. In the Framingham
Heart Study, it was reported that participants without
hypertension and with PWV below a low threshold (deter-
mined from European reference values [17]), as markers of
HVA, had less cardiovascular risk factors in general and less
changes to the arterial system, associated with a lower
prospective risk of cardiovascular events [16]. Another
recent American study focused on coronary artery calcium
(CAC) nondevelopment as hallmarks of HVA in the MESA
Study [18], and concluded that participants with persistent
CAC¼ 0 were individuals with lower long-term cardiovas-
cular risk than expected from individual cardiovascular risk
factors. As an alternative to the two previous definitions,
hypothesizing that ageing cannot be avoided but active and
healthy ageing is an achievable goal, HVA will account the
lowest end of the PWV distribution of a given population:
for example, the lowest 10% according to age category,
without consideration of hypertension or treatment status.
We used data from the international MARE cohort col-
laboration [19], including PWV measurements in approxi-
mately 20 000 individuals free of clinical overt
cardiovascular disease to apply this simplified definition.
The primary aim of the present analyses was, therefore, to
describe the risk factor profile of HVA participants (using an
alternative definition of HVA – 10% lowest of PWV distri-
bution) from MARE for a better representativeness of a
global population and based on data from a wide age range
of both sex. A secondary aimwas to investigate whether the
prevalence and the risk factor profile of HVA changed with
advancing age.
PARTICIPANTS ANDMETHODS
The Metabolic syndrome and Artery REsearch
Consortium
The original MARE (Metabolic syndrome and Artery
REsearch) Consortium was established as a collaboration
among European, American, and Asian Centers studying
population-based cohorts to identify any cross-cultural
differences in clustering of metabolic syndrome, its altered
components and associations with arterial ageing; to disen-
tangle the specific role of genes and lifestyle factors (and
their interactions) on the clinical presentation of MetS and
on the cardiovascular risk attributable to MetS; and to
develop new strategies to prevent cardiovascular events
through identification of lifestyle changes. The MARE2 www.jhypertension.comConsortium and measured variables has been previously
described, for details see [19].
Each study had been approved by local Institutional
Review Board or Ethical Committee and each participant
gave informed consent. All studies participating in the
MARE Consortium adhere to the principles of the Declara-
tion of Helsinki and Title 45, U.S. Code of Federal Regu-
lations, Part 46, Protection of Human Subjects, Revised 13
November 2001, effective 13 December 2001. The cohorts
participating to the present analysis are briefly described in
Supplemental Material, http://links.lww.com/HJH/A961.
Pulse wave velocity measurements
PWV was measured noninvasively and calculated from
foot-to-foot delay between carotid and femoral artery
waveforms and body surface measurement of the distance
between carotid and femoral pulse recording sites. In
accordance with recent recommendations [17], PWV mea-
sured in each cohort was ‘normalized’ as follows:
For devices entering the direct distance (common carotid
artery–common femoral artery):
PWV ‘normalized’¼PWV measured 0.8.
For devices entering the subtracted distance (common
carotid artery–common femoral artery):
PWV ‘normalized’¼PWV measured.
Definition of healthy vascular ageing and early
vascular ageing
For this analysis, we excluded all participants with coronary
and cerebrovascular disease according to self-reported
medical history and medical records. Thus, 18 490 partic-
ipants from the MARE Consortium free of cardiovascular
disease in whom PWV had been assessed represented our
study population.
There is at present no clear definition of HVA. Therefore,
we adopted two definitions of HVA: the first one was
undertaken based on the idea that ageing is not an avoid-
able phenomenon, but healthy ageing is possible and
represents a life-long condition. The second definition
referred to arterial ageing as an avoidable phenomenon.
Therefore, in the first definition, HVA was defined as a
PWV value below the age-quintile specific 10th percentile –
given that PWV is a highly age-associated trait. For the
second definition, we adopted an approach similar (but not
identical) to the one proposed by a previous study [15], that
is, we identified the lower 10th percentile of PWV distribu-
tion in younger participants (age <35 years) with normal
blood pressure levels as reference. The first definition was
adopted for the primary analysis of the current study.
Correspondingly, EVA was defined as a PWV value above
the age-quintile specific 90th percentile. Figure 1 illustrates
the trend in the age-specific threshold values of PWV
adopted to define HVA and EVA.Statistical methods
All analyses were performed using the SAS package for
Windows (9.1 Version Cary, North Carolina, USA). Data are
presented as mean SD or proportions, unless otherwise
specified. Student’s t-test was adopted to compare means in
participants without and with HVA. ANOVA analysis wasVolume 36  Number 1  Month 2018
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FIGURE 1 Age-specific lower (10th) and upper (90th) percentile for PWV in partic-
ipants without prevalent cardiovascular disease (myocardial infarction and/or
stroke).
Healthy vascular ageing in a global studyadopted to compare variables across age groups. ANCOVA
analysis was adopted to compare means across groups after
controlling for age, sex, and hypertension.
The definition of HVA based upon age-specific PWV
lower percentiles was adopted for further statistical model-
ling. To have some insight as to whether factors protecting
from arterial ageing are the same that, when elevated,TABLE 1. Characteristics of participants with healthy vascular ageing
definitions (see Methods)
HVA defined as PWV value belo
age-quintile specific 10th perce
Control (n¼16803) HVA (n¼1723)
Age (years) 52.516.5 52.417.1
Women (%) 57.0 59.4
BMI (kg/m2) 27.15.2 25.24.2
Waist circumference (cm) 91.014.0 85.112.8
Fasting glucose (mg/dl) 96.124.6 88.918.2
Total cholesterol (mg/dl) 218.450.2 204.341.8
HDL cholesterol (mg/dl) 58.418.7 63.417.5
Non-HDL cholesterol (mg/dl) 160.151.9 140.940.7
Triglycerides (mg/dl) 117.4123.9 87.159.2
SBP (mmHg) 131.519.5 120.516.7
DBP (mmHg) 79.711.5 73.310.2
MAP (mmHg) 96.813.0 89.011.3
PP (mmHg) 52.014.1 47.412.4
HR (bpm) 67.711.1 64.610.2
Central SBP (mmHg)a (n) 125.719.8 (8354) 117.318.5 (367)
Central PP (mmHg)a 43.714.4 41.414.5
PP amplification (%)a 131.730.7 128.221.9
Serum creatinine (mg/ml)a (n) 0.850.26 (13632) 0.840.19 (1685
PWV (m/s) 8.82.9 5.50.9
PWV/MBP 9.22.8 6.31.2
CCA IMT (mm)a (n) 0.700.25 (9916) 0.580.13 (1349
Hypertension (%) 41.8 21.0
Diabetes mellitus (%) 10.1 4.7
Overweight (%) 14.2 17.0
Obesity (%) 23.4 12.5
Metabolic syndrome 23.0 8.4
N of altered MetS components 1.51.3 0.81.1
Low HDL cholesterol 24.1 13.1
Elevated waist circumference 39.9 27.0
Elevated triglycerides 21.6 9.6
Elevated blood pressure 49.2 25.6
Elevated fasting glucose 18.2 7.9
Means (SD) and proportions (%). Definitions of the metabolic syndrome [17] needed for elevate
women. Elevated waist circumference greater than 102 cm for men or greater than 88 cm for w
130 mmHg/at least 85 mmHg or use of antihypertensive medications. Elevated fasting glucose a
heart rate; HVA, healthy vascular ageing; PP, pulse pressure; PWV, pulse wave velocity.
aMeasurement not available for each participant.
Journal of Hypertensionaccelerates arterial ageing, we compared cardiometabolic
risk profile in participants with HVA or with EVA, and with
all those without HVA. Multivariable logistic regression
analysis was, therefore, adopted to identify determinants
of HVA and EVA. A two-sided P value less than 0.05
indicated statistical significance.RESULTS
Primary analysis was conducted adopting age-specific
(quintile) lower 10th percentile to define HVA. The 1723
HVA participants were at same age as the rest of the
population, more likely women (59.4 vs. 57.0%), and with
significantly lower levels of established cardiovascular risk
factors (blood pressure, lipids, glucose) – as illustrated in
Table 1, left columns. Similarly, the prevalence rate of
obesity (but not overweight), diabetes mellitus, hyperten-
sion, low HDL cholesterol, and the metabolic syndrome
was much lower in the HVA participants. By construction,
PWVwas significantly lower in the HVA group, 5.5 (SD: 0.9)
vs. 8.8 (2.9) m/s (P< 0.0001).and the general study population (controls), based on the two
w the
ntile
HVA defined as PWV lower than 4.3m/s, that
is, 10th percentile in the younger (<35 years)
normotensive population
P value Control (n¼18238) HVA (n¼288) P value
0.76 53.016.2 22.310.6 0.0001
.05 57.1 64.2 0.01
.0001 27.05.1 21.12.9 0.0001
0.0001 90.713.9 73.37.8 0.0001
0.0001 95.724.3 79.49.3 0.0001
0.0001 217.849.5 171.730.7 0.0001
0.0001 58.818.8 61.813.7 0.0001
0.0001 159.151.2 109.927.8 0.0001
0.0001 115.5120.3 57.931.7 0.0001
0.0001 130.719.4 111.610.7 0.0001
0.0001 79.311.6 68.57.0 0.0001
0.0001 96.313.0 82.97.3 0.0001
0.0001 51.714.1 43.48.4 0.0001
0.0001 67.411.0 67.311.2 0.89
0.0001 125.419.8 (8710) 103.413.7 (11) 0.0001
0.01 43.614.4 31.37.4 0.01
0.05 131.530.4 160.127.6 0.01
) 0.01 0.850.26 (15029) 0.760.15 (288) 0.0001
0.0001 8.62.9 4.00.2 0.0001
0.0001 9.02.8 4.90.5 0.0001
) 0.0001 0.690.24 (10992) 0.480.06 (273) 0.0001
0.0001 40.5 27.8 0.0001
0.0001 9.7 3.5 0.0001
0.01 14.6 5.2 0.0001
0.0001 22.7 1.7 0.0001
0.0001 22.0 0 0.0001
0.0001 1.51.3 0.20.4 0.0001
0.0001 23.2 11.1 0.0001
0.0001 39.3 2.4 0.0001
0.0001 20.8 1.4 0.0001
0.0001 47.7 4.5 0.0001
0.0001 17.6 0.3 0.0001
d variables: low HDL cholesterol less than 40 mg/dl for men or less than 50 mg/dl for
omen. Elevated triglycerides at least 150 mg/dl. Elevated blood pressure at least
t least 10 mg/dl or use of antidiabetic medications. HDL, high-density lipoprotein; HR,
www.jhypertension.com 3
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TABLE 2. Determinants of healthy vascular ageing bymultivariable logistic regression analysis, by use of the two definitions (seeMethods)
HVA defined as PWV value below the
age-quintile specific 10th percentile
HVA defined as PWV lower than 4.3m/s,
that is, 10th percentile in the younger
(<35 years) normotensive population
OR 95% CI P value OR 95% CI P value
Age (per year) 0.985 0.982–0.988 0.0001 1.17 1.15 – 1.19 0.0001
Female sex 1.06 0.95 – 1.18 0.32 1.44 1.10 – 1.89 0.01
Diabetes mellitus 1.30 0.92 – 1.86 0.14 N /A N /A
Low HDL cholesterol 0.60 0.52 – 0.70 0.0001 0.86 0.57 – 1.28 0.45
Elevated waist circumference 0.76 0.66 – 0.86 0.0001 0.22 0.10 – 0.47 0.0001
Elevated triglycerides 0.57 0.48 – 0.68 0.0001 0.40 0.15 – 1.11 0.07
Elevated blood pressure 0.36 0.32 – 0.40 0.0001 0.37 0.21 – 0.66 0.001
Elevated fasting glucose 0.43 0.32 – 0.57 0.0001 0.35 0.08 – 2.61 0.30
95% CI, 95% confidence intervals; HDL, high-density lipoprotein; HVA, healthy vascular ageing; OR, odds ratios; PWV, pulse wave velocity.
Nilsson et al.A multivariable logistic regression model was con-
structed to identify determinants of the HVA condition as
illustrated in Table 2, left columns. As expected, controlled
cardiometabolic risk factors were all associatedwith a lower
likelihood of presenting HVA. Advancing chronological
age was associated with a significantly decreased likelihood
of having HVA. Per each 5 years increase in age, there
was approximately a 7% lower likelihood of having
HVA characteristics.
Secondary analysis was conducted adopting the younger
and healthier (normal BP) segment of population as refer-
ence. Notably the overall prevalence of HVA in the study
population was much lower with this definition (288
vs.1723 participants with the other definition). This was
attributable to the lack of HVA in participants older than age
40 years. Even with such definition, participants with HVA
had significantly lower levels of established cardiovascular
risk factors (blood pressure, lipids, glucose) – as illustrated
in Table 1, right columns and elevated BP and abdominal
obesity were associated with lower likelihood of having
HVA (Table 2, left columns).
The definition of HVA based upon age-specific PWV
lower percentile was adopted for further statistical model-
ling. To have some insight as to whether factors protecting
from arterial ageing are the same that accelerates arterial
ageing, we compared cardiometabolic risk profile in par-
ticipants with HVA, with EVA, and with controls. PWV
remained significantly lower in the HVA group after adjust-
ment for age, sex, and hypertension (P< 0.0001), Table 3.
Age and age-associated changes in profile of
healthy vascular ageing
As PWV significantly increases with advancing age and that
cardiometabolic risk factors impacting on arterial ageing
vary with advancing age, we compared the characteristic of
HVA participants in four different age groups: less than 35
years, 35–40 years, 50–64 years, 65 years and older, in
Table 4.
No significant difference in the age-distribution or sex-
distribution between HVA participants and controls were
observed in any age group. Furthermore, age-group belong-
ing did not impact on relative differences in cardiometabolic
risk factors between HVA participants and the rest.
Notably, in the presence of similar levels of cardiome-
tabolic risk factors, those without HVA in the age group4 www.jhypertension.com35–49 years (mean age 42.5 4.0 years) had significantly
stiffer (older) arteries (PWV: 7.4 1.4 vs. 5.8 0.5m/s,
respectively) as compared with HVA participants in the
age group 50–64 years (mean age 56.5 4.5 years), even in
the presence of similar average levels in blood pressure,
adiposity, blood lipids, and glucose. Similar comparisons
were made for the metabolic syndrome and its components
in participants with HVA and EVA as compared with the rest
of the population when stratified by age groups, Table 5.
Determinants of healthy vascular ageing and
early vascular ageing in age groups by multiple
regression analysis
We investigated determinants of HVA and EVA, as com-
pared with their counterparts and stratified by age groups.
As illustrated in Table 6, low HDL cholesterol, elevated
triglycerides, and elevated BP were associated with lower
likelihood of HVA in any age group. Elevated glucose was
associated with lower likelihood of having HVA in younger
and older participants, whereas abdominal adiposity
reduced the likelihood of having HVA in participants less
than 35 years of age. Elevated glucose and BP were consis-
tently associated with greater likelihood of having EVA
regardless of age. Abdominal adiposity and elevated tri-
glycerides conferred greater likelihood of having EVA up to
the age of 65, whereas low HDL cholesterol was associated
with greater likelihood of EVA in all but the youngest
age group.
DISCUSSION
Overall we found that participants characterized by HVA,
that is, with PWV values in the lowest 10% range of the age-
specific and quintile-specific distribution, had a more
favourable cardiovascular risk profile, and that both the
HVA and EVA phenotypes were determined by the same
cardiovascular risk factors. However, for the same levels of
cardiovascular risk factors, PWV was lower in HVA partic-
ipants, even 14 years older in chronological age than
younger control participants.
The recently published data from the Framingham Heart
Study (FHS) on HVA used another definition, based on the
absence of hypertension in combination with PWV values
below a specified low threshold [16] that even could be
regarded as arbitrary. The mean PWV of the HVAVolume 36  Number 1  Month 2018
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TABLE 3. Characteristics and differences between participants with healthy vascular ageing (first definition), controls, and early vascular
ageing in the Metabolic syndrome and Artery Research Consortium
HVA
(n¼1723)
Control
(n¼14866)
EVA
(n¼1937)
ANCOVA (adjusted for age,
sex, hypertension) P for trend
Age (years) 52.417.1 52.516.5 52.216.2 —
Women (%) 59.4 58.4 45.7 —
BMI (kg/m2) 25.24.2 27.15.1 27.85.3 0.0001
Waist circumference (cm) 85.112.8 90.714.0 93.313.8 0.0001
Fasting glucose (mg/dl) 88.918.2 95.723.4 99.230.1 0.0001
Total cholesterol (mg/dl) 204.341.8 217.850.2 223.250.1 0.0001
HDL 0cholesterol (mg/dl) 63.417.5 59.018.8 53.817.6 0.0001
Non-HDL cholesterol (mg/dl) 140.940.7 158.951.9 169.551.1 0.0001
Triglycerides (mg/dl) 88.856.0 114.6120.0 138.7148.4 0.0001
SBP (mmHg) 120.516.7 130.318.9 140.221.6 0.0001
DBP (mmHg) 73.310.2 79.011.2 84.812.8 0.0001
MAP (mmHg) 89.011.3 96.012.6 103.114.4 0.0001
PP (mmHg) 47.412.4 51.513.8 46.016.9 0.001
HR (bpm) 64.610.2 67.311.0 70.911.6 0.0001
Central SBP (mmHg)a 117.318.5 (367) 125.119.1 (7290) 130.123.5 (1064) 0.0001
Central PP (mmHg)a 41.414.5 43.413.9 46.016.9 0.0001
Serum creatinine (mg/ml)a 0.840.19 0.850.25 0.890.37 0.0001
PWV (m/s) 5.50.9 8.22.2 13.13.8 0.0001
PWV/MBP 6.31.2 8.72.2 12.83.8 0.0001
CCA IMT (mm)a 0.580.13 (1349) 0.690.24 (9148) 0.850.31 (768) 0.0001
PP amplification (%)a (n) 128.221.9 (367) 131.630.4 (7290) 132.433.0 (1064) 0.01
Hypertension (%) 26.3 44.1 48.3 —
Diabetes mellitus (%) 4.6 8.7 11.0 0.0001
Overweight (%) 17.0 14.3 13.5 0.01
Obesity (%) 12.4 23.0 26.0 0.0001
Metabolic syndrome 8.4 24.4 31.9 0.0001
N of altered MetS components 0.81.1 1.51.3 1.91.3 0.0001
Low HDL cholesterol 13.1 21.8 31.5 0.0001
Elevated waist circumference 27.0 39.8 40.9 0.0001
Elevated triglycerides 9.6 20.6 29.6 0.0001
Elevated blood pressure 25.6 46.9 67.0 0.0001
Elevated fasting glucose 7.9 17.8 21.8 0.0001
Means (SD) and proportions (%). Definitions of the metabolic syndrome [17] needed for elevated variables: Low HDL cholesterol less than 40 mg/dl for men or less than 50 mg/dl for
women. Elevated waist circumference greater than 102 cm for men or greater than 88 cm for women. Elevated triglycerides at least 150 mg/dl. Elevated blood pressure at least
130 mmHg/at least 85 mmHg or use of antihypertensive medications. Elevated fasting glucose at least 110 mg/dl or use of antidiabetic medications. CCA IMT, common carotid artery
intima-media thickness; EVA, early vascular ageing; HDL, high-density lipoprotein; HR, heart rate; HVA, healthy vascular ageing; MetS, metabolic syndrome; PP, pulse pressure; PWV,
pulse wave velocity.
aMeasurement not available for each participant.
Healthy vascular ageing in a global studyparticipants in the Framingham study was 6.8 (SD: 0.5) m/s,
as compared with 5.5 (0.9) m/s in our MARE study. In Cox
regression models adjusted for traditional CVD risk factors,
including blood pressure, HVA in Framingham was associ-
ated with a hazard ratio of 0.45 (95% confidence interval
0.26–0.77) for CVD relative to absence of HVA [16]. The
authors concluded that HVA was rare beyond 70 years of
age [16]. The advantage of the FHS is that outcomes could
be calculated during follow-up, but, on the other hand, the
MARE consortium offers a larger total study data-base and
age group-based sub-analyses for description of HVA on a
global scale. Their PWV lower values (<7.6m/s) corre-
spond to the HVA participants (lowest 10th percentile) of
age-group 70–74 years, or to EVA participants (upper 90th
percentile) of age-group 30–34 years in the present study.
It is also worth noting that if we were to use the FHS
definition of HVA [16], we would not find a single partici-
pant fitting this definition in our population above the age
of 40 years. This could be partially explained by a selection
bias in our global population, but we would also like to
discuss this as a possible hint that the definition of HVA
based on the concept of ‘no aging after 30 years of age’ isJournal of Hypertensionprobably inadequate to characterize HVA after the age of
40. We consider that the ageing process has been, up until
now, shown to be an inevitable process that can, at its best,
be slowed down, but not reversed, by controlling cardio-
vascular risk factors and pursuing healthy lifestyle.
In the MARE collaboration, we preferred to use a sim-
plified approach, only focusing on participants at the lower
10% end of the PWV. However, we also adjusted for the use
of cardiovascular drugs, when hypertension status was a
proxy for such drug usage. However, at present, we do not
have access to follow-up prospective data in the MARE
cohort collaboration making prospective analyses for risk
of incident cardiovascular events impossible. Furthermore,
the residual risk associated with genetic, cultural, lifestyle,
and ethnic diversity will most likely influence the long-term
health consequences associated with HVA, why direct
comparisons with Framingham will be difficult.
We adopted our approach (definition) because we did
not want to recommend to avoid ageing, as indicated in the
Framingham paper [16], but rather to age well. To have
some insight as to whether factors protecting from arterial
ageing are the same that accelerates arterial ageing, wewww.jhypertension.com 5
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TABLE 4. Cardiometabolic risk profile in participants with healthy vascular ageing or early vascular ageing as compared with controls
when stratified by age groups
< 34 years
HVA (n¼281) Control (n¼2404) EVA (n¼320) ANCOVA P for trend
Age (years) 24.26.7 25.85.7 26.35.0 0.0001a
Women (%) 69.0 57.1 46.9 0.0001a
BMI (kg/m2) 21.52.8 23.13.7 24.75.0 0.0001
Waist circumference (cm) 74.49.0 79.710.9 85.913.6 0.0001
Fasting glucose (mg/dl) 79.18.5 80.716.6 79.816.3 0.0001
Total cholesterol (mg/dl) 176.832.8 186.036.3 186.539.1 0.0001
HDL cholesterol (mg/dl) 62.313.6 60.515.3 54.614.8 0.0001
Not HDL cholesterol (mg/dl) 114.529.2 125.433.7 131.839.6 0.0001
Triglycerides (mg/dl) 62.032.8 76.145.4 91.472.5 0.0001
SBP (mmHg) 110.810.2 117.012.2 123.115.4 0.0001
DBP (mmHg) 69.17.5 71.67.9 75.610.5 0.0001
MBP (mmHg) 83.17.4 86.78.3 91.311.3 0.0001
PP (mmHg) 42.28.3 45.79.7 47.610.3 0.0001
HR (bpm) 66.710.5 67.711.7 71.211.8 0.0001
Serum creatinine (mg/ml)b (n) 0.760.14 (281) 0.790.16 (2394) 0.820.17 (316) 0.0001
PWV (m/s) 4.10.4 5.40.8 8.52.3 0.0001
PWV/MAP 5.00.5 6.31.0 9.32.8 0.0001
35–49 years
HVA (n¼376) Control (n¼3345) EVA (n¼438) ANCOVA P for trend
Age (years) 42.34.0 42.23.9 42.24.0 0.88a
Women (%) 64.1 48.4 34.0 0.0001a
BMI (kg/m2) 24.33.6 26.54.7 28.25.4 0.0001
Waist circumference (cm) 81.010.9 88.613.8 93.114.1 0.0001
Fasting glucose (mg/dl) 84.011.5 91.020.2 95.520.9 0.0001
Total cholesterol (mg/dl) 202.935.2 215. 646.0 220.645.1 0.01
HDL cholesterol (mg/dl) 64.014.3 57.617.0 50.616.0 0.0001
Non-HDL cholesterol (mg/dl) 138.834.8 158.048.5 170.347.6 0.0001
Triglycerides (mg/dl) 77.145.0 126.864.8 170.6182.8 0.0001
SBP (mmHg) 116.112.4 124.917.0 134.521.1 0.0001
DBP (mmHg) 74.09.0 80.311.4 87.513.1 0.0001
MAP (mmHg) 88.19.5 95.012.5 103.014.9 0.0001
PP (mmHg) 42.57.9 44.710.4 47.113.2 0.05
HR (bpm) 64.110.6 67.911.2 70.311.5 0.0001
Serum creatinine (mg/ml)b (n) 0.800.15 (373) 0.840.25 (2679) 0.920.50 (295) 0.01
PWV (m/s) 5.00.4 7.41.4 11.62.0
PWV/MAP 5.80.7 7.91.6 8.92.3
50–64 years
HVA (n¼613) Control (n¼5268) EVA (n¼692) ANCOVA P for trend
Age (years) 56.64.6 56.74.5 56.34.5 0.05a
Women (%) 54.7 48.0 50.6 0.0001a
BMI (kg/m2) 26.74.2 29.35.2 29.25.4 0.0001
Waist circumference (cm) 88.912.5 95.913.6 96.513.6 0.0001
Fasting glucose (mg/dl) 92.821.9 100.925.1 104.834.3 0.0001
Total cholesterol (mg/dl) 218.944.2 240.253.1 243.448.6 0.0001
HDL cholesterol (mg/dl) 64.319.2 57.819.5 53.717.5 0.0001
Non-HDL cholesterol (mg/dl) 154.744.5 182.456.3 189.750.1 0.0001
Triglycerides (mg/dl) 103.175.7 146.0134.7 166.6178.7 0.0001
SBP (mmHg) 123.015.9 134.418.0 145.120.2 0.0001
DBP (mmHg) 76.310.5 83.110.5 88.711.9 0.0001
MAP (mmHg) 91.811.5 100.012.1 107.313.5 0.0001
PP (mmHg) 46.710.2 51.312.6 56.414.5 0.0001
HR (bpm) 64.89.9 67.110.6 70.211.7 0.0001
Serum creatinine (mg/ml)b (n) 0.830.17 (596) 0.830.22 (3935) 0.860.22 (324) 0.01
PWV (m/s) 5.80.5 8.81.4 13.62.5 0.0001
PWV/MAP 6.41.0 8.91.7 13.02.9 0.0001
65þ years
HVA (n¼452) Control (n¼3849) EVA (n¼487) ANCOVA P for trend
Age (years) 72.55.7 72.55.5 72.35.1 0.74a
Women (%) 56.0 60.4 48.9 0.0001a
BMI (kg/m2) 26.13.9 27.24.3 27.64.5 0.0001
Nilsson et al.
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TABLE 4 (Continued)
65þ years
HVA (n¼452) Control (n¼3849) EVA (n¼487) ANCOVA P for trend
Waist circumference (cm) 90.011.7 92.512.1 93.912.0 0.001
Fasting glucose (mg/dl) 94.018.1 102.523.4 107.631.5 0.0001
Total cholesterol (mg/dl) 202.939.5 209.843.7 221.448.4 0.0001
HDL cholesterol (mg/dl) 62.419.7 60.621.0 56.120.3 0.001
Not HDL cholesterol (mg/dl) 140.437.5 149.242.2 165.347.1 0.0001
Triglycerides (mg/dl) 89.449.2 86.655.3 102.366.6 0.0001
SBP (mmHg) 126.620.1 138.219.1 149.519.3 0.0001
DBP (mmHg) 71.210.9 77.110.9 83.011.8 0.0001
MAP (mmHg) 89.512.6 97.312.4 105.012.7 0.0001
PP (mmHg) 45.917.7 61.014.6 56.116.6 0.0001
HR (bpm) 63.49.7 66.810.8 72.211.3 0.0001
Serum creatinine (mg/ml)b (n) 0.940.23 (435) 0.930.31 (3378) 0.980.46 (311) 0.07
PWV (m/s) 6.40.7 10.11.9 16.63.8 0.0001
PWV/MAP 7.31.3 10.52.1 16.03.8 0.0001
ANCOVA, analysis of covariance; EVA, early vascular ageing; HDL, high-density lipoprotein; HR, heart rate; HVA, healthy vascular ageing; MAP, mean arterial pressure; MetS, metabolic
syndrome; PP, pulse pressure; PWV, pulse wave velocity.
aANOVA (analysis of variance).
bMeasurement not available for each participant.
Healthy vascular ageing in a global studycompared the cardiometabolic risk profile in participants
with HVA, with EVA, and with controls.
Although cardiovascular morbidity and mortality
remains very high even at older ages, it has been reported
that traditional cardiovascular risk factors, such as obesity
and serum cholesterol, are associated with lower, rather
than higher, risk of cardiovascular events in older individ-
uals [10,20]. This is the so called ‘reverse epidemiology’ or
‘risk factor paradox.’ Regardless of whether this paradox is
attributable to healthy selection survival bias or, more
simply, to a reduced burden of factors risky at younger
ages, we compared cardiometabolic risk factor distribution
across participants belonging to HVA, EVA, or controls in
four age groups: less than 35 years, 35–49 years, 50–64
years, 65þ years. When stratified for age groups (Tables 4–
6) the trend in cardiovascular risk factor levels were roughly
similar across age groups.
The major limitation of the present study is represented
by its cross-sectional design and use of different methods
for estimation of reported cardiovascular risk factors and
PWV, as previously described [19]. Selection bias could vary
between cohorts with shifting representativeness of the
background population in each country. On the other
hand, a major strength is represented by the adoption of
the lowest 10% of the PWVdistribution within age groups of
each studied population (cohort) to define HVA as com-
pared with previous report adopting ‘external reference
value’ [17].
The global nature of the MARE consortium makes our
data of interest to understand the HVA phenotype in a
broader sense, reflecting the global perspective. As the
cardiovascular risk in general undergoes time-dependent
changes over time, with decreasing age-adjusted trends in
many western countries, but increasing trends in countries
with populations in transition, this could mean that the
importance of HVA is also time-dependent and cohort-
dependent, reflecting cohort characteristics at a certain
historical time window. Increased knowledge about HVA
and its characteristics could benefit the design of preventiveJournal of Hypertensionprojects for vascular protection by lifestyle improvement or
drug intervention in EVA participants [12,13,21], the inverse
of HVA. The increased use of drugs believed to limit or
reverse PWV increasing with age, and the complex nature
of drug treatments in each individual makes this confound-
ing factor difficult, if not impossible to control in the
present study.
Future studies, including genetic mapping of HVA and
related protective mechanisms could eventually reveal pos-
sible new drug targets, to be tested in controlled studies.
From the wider perspective of Active and Healthy Aging
(AHA), it is thus of importance to better understand deter-
minants of HVA (genetics, environment, lifestyle, and
drugs) to support precision care [22]. The observation that
both HVA and EVA was determined by the same cardiovas-
cular risk factors indicates that treatment of these cardio-
vascular risk factors might shift the vascular ageing away
from EVA towards HVA.
The future perspective may thus change from the treat-
ment of cardiovascular risk factors only, to a more integra-
tive approach associating protective factors to preserve
functional reserve and independency in the daily activity
[23]. It is necessary that these aspects are studied in different
ethnic populations, and a recent report from Shanghai
concluded that target organ damage was associated with
elevated PWV, but at the lower end of the PWV distribution,
corresponding to HVA in Chinese individuals, far less TOD
was noticed [24].
In conclusion, we report characteristics of HVA on a
global scale and that these participants, belonging to the
lowest end of the PWV distribution, are in general charac-
terized by an up to 14 years younger biological age than
controls, selected from the rest of the distribution. We have
also shown that different factors contribute to HVA in
different age groups, paving the way for differentiated
public health policies according to age and sex. These
insights could guide preventive work and the communica-
tion with participants at elevated risk to improve their own
vascular age as reflected by elevated PWV.www.jhypertension.com 7
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TABLE 5. Metabolic syndrome and its components in participants with healthy vascular ageing and early vascular ageing, as compared
with controls, when stratified by age groups
< 34 years
HVA (n¼281) Control (n¼2404) EVA (n¼320) ANCOVA P for trend
Hypertension (%) 4.6 8.7 21.6 –
Diabetes mellitus (%) – 0.5 1.9 0.21
Overweight (%) 6.4 10.6 13.4 0.0001
Obesity (%) 1.4 4.9 10.9 0.20
Metabolic syndrome – 2.0 7.8 0.0001
N of altered MetS components 0.20.4 0.50.7 0.91.0 0.0001
Low HDL cholesterol 8.9 13.6 22.5 0.0001
Elevated waist circumference 4.6 11.5 22.2 0.0001
Elevated triglycerides 0.7 5.4 11.9 0.001
Elevated blood pressure 3.2 13.8 28.8 0.0001
Elevated fasting glucose – 1.0 3.1 0.01
35–49 years
HVA (n¼376) Control (n¼3345) EVA (n¼438) ANCOVA P for trend
Hypertension (%) 10.6 28.2 48.9 –
Diabetes mellitus (%) 0.3 4.9 8.0 0.05
Overweight (%) 18.6 14.4 13.9 0.10
Obesity (%) 6.1 18.5 23.5 0.01
Metabolic syndrome 2.1 15.8 29.2 0.0001
N of altered MetS components 0.40.7 1.21.2 1.81.3 0.0001
Low HDL cholesterol 6.9 20.8 36.1 0.0001
Elevated waist circumference 12.5 27.4 32.6 0.0001
Elevated triglycerides 5.9 22.8 38.6 0.0001
Elevated blood pressure 15.2 38.1 60.5 0.0001
Elevated fasting glucose 0.8 10.3 16.2 0.0001
50–64 years
HVA (n¼613) Control (n¼5268) EVA (n¼692) ANCOVA P for trend
Hypertension (%) 22.6 44.3 66.0 –
Diabetes mellitus (%) 6.0 13.4 16.6 0.05
Overweight (%) 20.0 13.4 11.1 0.001
Obesity (%) 19.9 35.7 34.2 0.001
Metabolic syndrome 12.5 34.3 44.1 0.0001
N of altered MetS component 1.11.2 2.01.3 2.31.3 0.0001
Low HDL cholesterol 14.7 29.1 34.1 0.0001
Elevated waist circumference 34.7 56.6 52.6 0.0001
Elevated triglycerides 15.0 33.2 41.6 0.0001
Elevated blood Pressure 33.4 55.6 77.0 0.0001
Elevated fasting glucose 10.6 23.8 25.0 0.0001
65þ years
HVA (n¼452) Control (n¼3849) EVA (n¼487) ANCOVA P for trend
Hypertension (%) 37.6 62.4 82.3 –
Diabetes mellitus (%) 9.5 14.2 22.0 0.001
Overweight (%) 18.1 17.6 16.4 0.64
Obesity (%) 14.6 20.9 26.5 0.001
Metabolic syndrome 13.3 22.3 32.6 0.0001
N of altered MetS components 1.21.1 1.71.1 2.11.1 0.0001
Low HDL cholesterol 18.6 22.8 29.6 0.0001
Elevated waist circumference 42.7 45.2 43.7 0.86
Elevated triglycerides 10.8 10.8 16.2 0.01
Elevated blood pressure 37.6 63.3 83.8 0.0001
Elevated fasting glucose 15.0 26.6 34.5 0.0001
ANCOVA, analysis of covariance; EVA, early vascular ageing; HDL, high-density lipoprotein; HVA, healthy vascular ageing; MetS, metabolic syndrome.
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TABLE 6. Determinants of healthy vascular ageing and early vascular ageing as compared with controls, stratified by age groups
(multinomial logistic regression analysis)
< 35 years 35–49 years 50–64 years 65þ years
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
HVA
Age 1.00 0.98–1.02 0.97 0.94–0.99 0.84 0.82–0.85 0.99 0.98–1.01
Female sex 0.72 0.55–0.93 0.75 0.59–0.94 0.64 0.54–0.77 0.64 0.52–0.79
Elevated fasting glucose 0.30 0.17–0.80 0.85 0.62–1.16 1.04 0.85–1.26 0.75 0.61–0.92
Low HDL cholesterol 0.64 0.47–0.87 0.54 0.43–0.68 0.78 0.65–0.92 0.66 0.53–0.82
Elevated triglycerides 0.66 0.44–1.00 0.69 0.54–0.87 0.78 0.65–0.93 0.75 0.57–0.98
Elevated blood pressure 0.51 0.38–0.68 0.45 0.37–0.56 0.38 0.31–0.46 0.34 0.26–0.44
Elevated waist circumference 0.50 0.36–0.70 1.15 0.90–1.46 1.22 1.02–1.46 1.10 0.89–1.35
EVA
Age 0.96 0.94–0.99 1.07 1.04–1.10 1.01 0.99–1.03 1.00 0.99–1.02
Female sex 1.56 1.18–2.06 1.32 1.04–1.67 0.81 0.67–0.97 0.80 0.64–0.99
Elevated fasting glucose 7.54 2.37–24.0 1.75 1.33–2.31 1.97 1.50–2.58
Low HDL cholesterol 1.50 0.97–2.31 2.38 1.57–3.62 1.57 1.23–2.00 1.33 1.03–1.73
Elevated triglycerides 5.38 1.32–22.0 2.27 1.43–3.60 1.98 1.55–2.52 0.85 0.62–1.18
Elevated blood pressure 3.46 1.74–6.86 2.70 1.99–3.66 2.21 1.84–2.64 2.90 2.37–3.56
Elevated waist circumference 2.46 1.37–4.39 1.66 1.18–2.31 1.57 1.28 -1.91 0.88 0.71–1.10
Definitions of the metabolic syndrome [17] needed for elevated variables: low HDL cholesterol less than 40 mg/dl for men or less than 50 mg/dl for women. Elevated waist circumference
greater than 102 cm for men or greater than 88 cm for women. Elevated triglycerides at least 150 mg/dl. Elevated blood pressure at least 130 mmHg/at least 85 mmHg or use of
antihypertensive medications. Elevated fasting glucose at least 110 mg/dl or use of antidiabetic medications. 95% CI, 95% confidence intervals; EVA, early vascular ageing HDL, high-
density lipoprotein; HVA, healthy vascular ageing; OR, odds ratios.
Healthy vascular ageing in a global studyACKNOWLEDGEMENTS
We thank all participants in the cohorts for contributing
data to the MARE consortium as well as the funding agen-
cies supporting these cohorts.
Financial support: The Asklepios Study is supported by
the Fund for Scientific Research – Flanders (FWO research
grants G042703 and G083810N).
The Rotterdam Study is supported by the Erasmus
Medical Center and Erasmus University Rotterdam; the
Netherlands Organization for Scientific Research; the
Netherlands Organization for Health Research and Devel-
opment (ZonMw); the Research Institute for Diseases in the
Elderly (RIDE); the Netherlands Heart Foundation; the
Ministry of Education, Culture and Science; the Ministry
of Health Welfare and Sports; the European Commission;
and the Municipality of Rotterdam.
The SardiNIA team was supported by Contract NO1-AG-
1–2109 from the NIA. This research was supported in part
by the Intramural Research Program of the NIH, National
Institute on Aging (USA).
The Baltimore Longitudinal Study of Aging (BLSA) is
supported in part by the Intramural Research Program of
the NIH, National Institute on Aging.
The Kingmen Aging Study was supported, in part, by a
grant from the National Science Council (NSC 99-2314-B-
010-034-MY3), an intramural grant from the Taipei Veterans
General Hospital (grant V102C-119), Research and Devel-
opment contract NO1-AG-1–2118, and the Intramural
Research Program of the National Institute on Aging,
National Institutes of Health.
The Malmoe Diet Cancer – Cardiovascular Study was
supported by grants from the Swedish Research Council
(K2008-65X-20752-01-3, K2011-65X-20752-04-6), the Lund-
stro¨ms Foundation, the Swedish Heart-Lung Foundation
(2010-0244; 2013-0249) and ALF government grants (Dnr:
2012/1789).Journal of HypertensionThe Guimara˜es Study was funded by the Life and Health
Research Institute, Medical School, Minho University,
Portugal
Conflicts of interest
There are no conflicts of interest.
REFERENCES
1. O’Rourke MF, Safar ME. Relationship between aortic stiffening and
microvascular disease in brain and kidney: cause and logic of therapy.
Hypertension 2005; 46:200–204.
2. Scuteri A, Chen CH, Yin FCP, Yin FC, Chih-Tai T, Spurgeon HA, Lakatta
EG. Functional correlates of central arterial geometric phenotypes.
Hypertension 2001; 38:1471–1475.
3. Lacolley P, Regnault V, Segers P, Laurent S. Vascular smooth muscle
cells and arterial stiffening: relevance in development, aging, and
disease. Physiol Rev 2017; 97:1555–1617.
4. Ben-ShlomoY, SpearsM,BoustredC,MayM,Anderson SG,BenjaminEJ,
et al. Aortic pulse wave velocity improves cardiovascular event predic-
tion: an individual participantmeta-analysis of prospectiveobservational
data from 17,635 subjects. J Am Coll Cardiol 2014; 63:636–646.
5. Scuteri A, Tesauro M, Guglini L, Lauro D, Fini M, Di Daniele N. Aortic
stiffness and hypotension episodes are associated with impaired cog-
nitive function in older subjects with subjective complaints of memory
loss. Int J Cardiol 2013; 169:371–377.
6. Scuteri A, Morrell CH, Orru` M, Strait JB, Tarasov KV, Ferreli LA, et al.
Longitudinal perspective on the conundrum of central arterial stiffness,
blood pressure, and aging. Hypertension 2014; 64:1219–1227.
7. Tarasov KV, Sanna S, Scuteri A, Strait JB, Orru` M, Parsa A, et al. COL4A1
is associated with arterial stiffness by genome-wide association scan.
Circ Cardiovasc Genet 2009; 2:151–158.
8. Mitchell GF, Verwoert GC, Tarasov KV, Isaacs A, Smith AV, Yasmin.
et al. Common genetic variation in the 3’-BCL11B gene desert is
associated with carotid-femoral pulse wave velocity and excess car-
diovascular disease risk: the Aorta Gen Consortium. Circ Cardiovasc
Genet 2012; 5:81–90.
9. Scuteri A, Najjar SS, Orru’ M, Usala G, Piras MG, Ferrucci L, et al. The
central arterial burden of the metabolic syndrome is similar in men and
women: the SardiNIA Study. Eur Heart J 2010; 31:602–613.
10. Scuteri A, Orru’ M, Morrell CH, Tarasov K, Schlessinger D, Uda M,
Lakatta EG. Associations of large artery structure and function with
adiposity: effects of age, gender, and hypertension. The SardiNIA
Study. Atherosclerosis 2012; 221:189–197.www.jhypertension.com 9
CE: Tripti; JH-D-18-00226; Total nos of Pages: 10;
JH-D-18-00226
Nilsson et al.11. Scuteri A, Tesauro M, Rizza S, Iantorno M, Federici M, Lauro D, et al.
Endothelial dysfunction and arterial stiffness in normotensive nor-
moglycemic first degree relatives of diabetic patients are independent
of the metabolic syndrome. Nutr Metab Cardiovasc Dis 2008; 18:
349–356.
12. Nilsson PM, Boutouyrie P, Laurent S. Vascular aging: a tale of EVA and
ADAM in cardiovascular risk assessment and prevention. Hypertension
2009; 54:3–10.
13. Nilsson PM, Boutouyrie P, Cunha P, Kotsis V, Narkiewicz K, Parati G,
et al. Early vascular ageing in translation: from laboratory investigations
to clinical applications in cardiovascular prevention. J Hypertens 2013;
8:1517–1526.
14. Cunha PG, Cotter J, Oliveira P, Vila I, Boutouyrie P, Laurent S, Peter M.
Pulse wave velocity distribution in a cohort study: from arterial stiffness
to early vascular aging. J Hypertens 2015; 33:1438–1445.
15. Olsen MH, Angell SY, Asma S, Boutouryie P, Burger D, Chirinos JA,
et al. A call to action and a life course strategy to address the global
burden of raised blood pressure on current and future generations:
the Lancet Commission on hypertension. Lancet 2016; 388:
2665–2712.
16. Niiranen TJ, Lyass A, Larson MG, Hamburg NM, Benjamin EJ, Mitchell
GF, Vasan RS. Prevalence, correlates, and prognosis of healthy vascular
aging in a western community-dwelling cohort: the Framingham Heart
Study. Hypertension 2017; 70:267–274.10 www.jhypertension.com17. The Reference Values for Arterial Stiffness Collaboration. Determinants
of pulse wave velocity in healthy people and in the presence of
cardiovascular risk factors: ‘establishing normal and reference values’.
Eur Heart J 2010; 31:2338–2350.
18. Whelton SP, SilvermanMG,McEvoy JW, Budoff MJ, Blankstein R, Eng J,
et al. Predictors of long-term healthy arterial aging: coronary artery
calcium nondevelopment in the MESA Study. JACC Cardiovasc Imag-
ing 2015; 8:1393–1400.
19. Scuteri A, Laurent S, Cucca F, Cockcroft J, Cunha PG, Man˜as LR, et al.,
Metabolic Syndrome and Arteries Research (MARE) Consortium. Met-
abolic syndrome across Europe: different clusters of risk factors. Eur J
Prev Cardiol 2015; 22:486–491.
20. Ahmadi SF, Streja E, Zahmatkesh G, Streja D, Kashyap M, Moradi H,
et al. Reverse epidemiology of traditional cardiovascular risk factors in
the geriatric population. J Am Med Dir Assoc 2015; 16:933–939.
21. NowakKL, RossmanMJ, ChoncholM, Seals DR. Strategies for achieving
healthy vascular aging. Hypertension 2018; 71:389–402.
22. CurrieG,DellesC.Healthyvascular aging.Hypertension2017; 70:229–231.
23. Scuteri A, Lattanzio F, Bernabei R. Life-course approach to chronic
disease: the active and healthy aging perspective. J Am Geriatr Soc
2016; 64:e59–e61.
24. Ji H, Teliewubai J, Lu Y, Xiong J, Yu S, Chi C, et al. Vascular aging and
preclinical target organ damage in community-dwelling elderly: the
Northern Shanghai Study. J Hypertens 2018; 36:1391–1398.Volume 36  Number 1  Month 2018
